Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Several melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) have recently become available for the treatment of insomnia, depression and circadian rhythms sleep-wake disorders. The efficacy and safety profiles of these compounds in the treatment of the indicated disorders are reviewed. Accumulating evidence indicates that sleep-wake disorders and co-existing medical conditions are mutually exacerbating. This understanding has now been incorporated into the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Therefore, when evaluating the risk/benefit ratio of sleep drugs, it is pertinent to also evaluate their effects on wake and comorbid condition. Beneficial effects of melatonin receptor agonists on comorbid neurological, psychiatric, cardiovascular and metabolic symptomatology beyond sleep regulation are also described. The review underlines the beneficial value of enhancing physiological sleep in comorbid conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?
Ford, D. E. (1989) · JAMA · doi:10.1001/jama.1989.03430110069030 · Cited by 2,252
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Sleep and Alzheimer disease pathology--a bidirectional relationship
Ju, Y.-E. S., Lucey, B. P., & Holtzman, D. M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.269 · Cited by 996 · cited 1×
“Compelling evidence indicates a causal link between poor sleep and increased AD risk and memory loss [88–90].”
BackgroundBuysse, D. J. (2013) · JAMA · doi:10.1001/jama.2013.193 · Cited by 965
Place of chronic insomnia in the course of depressive and anxiety disorders
Ohayon, M. M., & Roth, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00052-3 · Cited by 873 · cited 1×
“04 to 6 times greater in patients with severe insomnia as compared to those without insomnia and increasing insomnia severity is associated with increased chronic medical and psychiatric illnesses [49,50].”
BackgroundLim, A. S. P., Kowgier, M., Yu, L., Buchman, A. S., & Bennett, D. A. (2013) · Sleep · doi:10.5665/sleep.2802 · Cited by 793 · cited 1×
“Compelling evidence indicates a causal link between poor sleep and increased AD risk and memory loss [88–90].”
BackgroundSleep Quality and Preclinical Alzheimer Disease
Ju, Y.-E. S., McLeland, J. S., Toedebusch, C. D., Xiong, C., Fagan, A. M., Duntley, S. P., Morris, J. C., & Holtzman, D. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2334 · Cited by 744 · cited 2×
“A recent study on sleep quality and preclinical AD demonstrated that Aβ deposition in the preclinical stage of AD is associated with worse sleep quality but not with changes in sleep quantity [92].”
BackgroundRole of Melatonin in the Regulation of Human Circadian Rhythms and Sleep
Cajochen, C., Kräuchi, K., & Wirz‐Justice, A. (2003) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2003.00989.x · Cited by 735 · cited 1×
“subjects [8].”
Jansson-Fröjmark, M., & Lindblom, K. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.10.016 · Cited by 646 · cited 1×
“rhythm sleep disorders [45,46].”
Self-reported sleep and β-amyloid deposition in community-dwelling older adults
Spira, A. P., Gamaldo, A. A., An, Y., Wu, M. N., Simonsick, E. M., Bilgel, M., Zhou, Y., Wong, D. F., Ferrucci, L., & Resnick, S. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4258 · Cited by 570 · cited 1×
“Poor sleep quality or short sleep, increase β amyloid burden in brain areas typically affected in AD [91,92].”
Background
Cited by
Melatonin as a Hormone: New Physiological and Clinical Insights
Cipolla-Neto, J., & Amaral, F. G. D. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00084 · Cited by 635
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
Liu, J., Clough, S. J., Hutchinson, A. J., Adamah-Biassi, E. B., Popovska-Gorevski, M., & Dubocovich, M. L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124742 · Cited by 630
Endogenous non-enzymatic antioxidants in the human body
Mirończuk-Chodakowska, I., Witkowska, A. M., & Zujko, M. E. (2018) · Advances in Medical Sciences · doi:10.1016/j.advms.2017.05.005 · Cited by 613
RONS and Oxidative Stress: An Overview of Basic Concepts
Aranda-Rivera, A. K., Cruz-Gregorio, A., Arancibia-Hernández, Y. L., Hernández-Cruz, E. Y., & Pedraza-Chaverri, J. (2022) · Oxygen · doi:10.3390/oxygen2040030 · Cited by 384
Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease
Chitimus, D. M., Popescu, M. R., Voiculescu, S. E., Panaitescu, A. M., Pavel, B., Zagrean, L., & Zagrean, A.-M. (2020) · Biomolecules · doi:10.3390/biom10091211 · Cited by 354
“5–2 h, with a metabolite with an even longer half-life (2–5 h) [25].”
BackgroundCerebral ischemia and neuroregeneration
Lin, H., Lee, R. C., Lee, M. H., Wu, C. C., Couto e Silva, A., Possoit, H., Hsieh, T.-H., & Minagar, A. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.228711 · Cited by 204
“Thus, melatonin has been widely used for the treatment of sleep disorders including insomnia, delayed sleep phase syndrome, and rapid eye movement sleep behavior disorder (Laudon and Frydman-Marom, 2014; Tordjman et al., 2017; Xie et al., 2017).”
Methodvan Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Circadian depression: A mood disorder phenotype
Carpenter, J. S., Crouse, J. J., Scott, E. M., Naismith, S. L., Wilson, C., Scott, J., Merikangas, K. R., & Hickie, I. B. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.045 · Cited by 114
Aiding sleep in type 2 diabetes: therapeutic considerations
Tan, X., van Egmond, L., Chapman, C. D., Cedernaes, J., & Benedict, C. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30233-4 · Cited by 72
GIRK Channels Mediate the Nonphotic Effects of Exogenous Melatonin
Hablitz, L. M., Molzof, H. E., Abrahamsson, K. E., Cooper, J. M., Prosser, R. A., & Gamble, K. L. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1597-15.2015 · Cited by 44
Rosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Metadata
- Authors
- Laudon, M., & Frydman-Marom, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2014-09-09
- Volume
- 15
- Issue
- 9
- Pages
- 15924-15950
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2158639142
- Cited by
- 149
- References
- 34
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.